Dose-related effect of moxisylyte on maximal urethral closing pressure in patients with spinal cord injuries.
The effects of single intravenous doses of 0.25, 0.50, and 0.75 mg/kg moxisylyte on maximum urethral closure pressure were evaluated in a placebo-controlled double-blind experiment in 20 patients with spinal cord injuries. Pharmacodynamic testing was performed until 30 minutes, and blood pressure was assessed until 60 minutes. Our findings showed a dose-dependent decrease in maximum urethral closure pressure. At each individual time point, the three doses differed significantly from placebo. Ten minutes after dose administration the maximum effect (48% decrease) was obtained with 0.75 mg/kg. A significant difference in favor of the highest dose was shown from 15 to 20 minutes after administration. According to these findings and because 0.75 mg/kg was as well tolerated as the two other doses, such a drop in pressure indicates that the alpha-blocking agent moxisylyte may be an effective means of decreasing urethral resistance, with obvious implications for the management of urinary obstruction.
Costa
P
P
Service d'Urologie-Andrologie, CHU G. Doumergue, Nîmes, Montpellier, France.
Bressolle
F
F
Sarrazin
B
B
Mosser
J
J
Sabatier
R
R
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013948:Moxisylyte / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D011312:Pressure; D013119:Spinal Cord Injuries / Q000503:physiopathology*; D014521:Urethra / Q000187:drug effects* / Q000503:physiopathology
D013948:Moxisylyte